These data strongly support that altered CLR expression profiles on DCs’ subsets from melanoma patients are linked with specific glycan patterns on melanoma tumor cells, but could also be related to the presence of necrotic cells or other released factors such as DAMPs. Here, DCLK3 is linked to melanoma.